Open Access#12018
Interim 2017/18 influenza seasonal vaccine effectiveness: Combined results from five European studies
Rondy M; Kissling E; Emborg H.-D; Gherasim A; Pebody R; Trebbien R; Pozo F; Larrauri A; McMenamin J; Valenciano M; Kaic B; Filipovic S.K; Visekruna-Vucina V; Novosel I.P; Lovric Z; Petrovic G; Krause T.G; Fische T.K; Lina B; Falchi A; Vilcu A.-M; Souty C; Blanchon T; van der Werf S; Enouf V; Behillil S; Valette M; Bernard-Stoecklin S; Levy-Bruhl D; Launay O; Loulergue P; Lenzi N; Lesieur Z; L'Honneur A.-S; Galtier F; Agostini C; Serrand C; Merle C; Foulongne V; Vanhems P; Laine F; Lagathu G; Carrat F; Buda S; Preuss U; Prahm K; Schweiger B; Wedde M; Heider A; Martin M; Biere B; Duerrwald R; Domegan L; Coughlan L; O'Donnell J; Joyce M; Collins C; Dunford L; Moran J; Tuite G; Duffy M; Connell J; de Gascun C; Rizzo C; Bella A; Alfonsi V; Castrucci M.R; Puzelli S; Pagani E; Ghisetti V; Pariani E; Baldanti F; Palu G; D'Agaro P; Ansaldi F; Affanni P; Rossolini G.M; Camilloni B; Bagnarelli P; Sanguinetti M; Atripaldi L; Chironna M; Serra C; Vitale F; Germinario C; Orsi A; Manini I; Montomoli E; Napoli C; Orsi G.B; Casado I; Castilla J; Fernandino L; Martinez-Baz I; Ezpeleta G; Navascues A; Perez-Garcia A; Aguinaga A; Ezpeleta C; Meijer A; van den Brink S; van der Hoek W; Goderski G; Wijsman L; Bagheri M; Dijkstra F; de Lange M; Marzec T; Overduin P; Teirlinck A; Wentink E; Donker G; Marbus S; van Gageldonk-Lafeber R; Schneeberger P; van Oosterheert J.J; Schweitzer V; Groeneveld G; Nunes B; Machado A; Rodrigues A.P; Gomez V; Kislaya I; Guiomar R; Pechirra P; Cristovao P; Costa I; Panarra A; Corte-Real R; Pocas J; Peres M.J; Comas L.G; Marisquerena M.E.I; Galan J.C; Folgueira M.D; Carril F.G; Martinez R.S; Cilla G; Cenoz M.G; Rubio C.Q; Ochoa E.M; Blasco M; Duran J.G; Vanrell J.M; Reina J; Castrillejo D; Gherasim A.M; Delgado C; Oliva J; Casas I; Garcia M; Latorre M; Beamonte A.M.M; Sapina A.M; Amores M.O; Aizpurua A; Montes M; Zakikhany K; Brytting M; Wiman A; Carnahan A; Warburton F; Djennad A; Ellis J; Andrews N; Marques D; Cottrell S; Reynolds A; Gunson R; Galiano M; Lackenby A; Robertson C; O'Doherty M; Sinnathamby M; Yonova I; Moore C; Sartaj M; de Lusignan S; Zambon M; Moren A; Penttinen P
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
